Soleno Q1 FY26 net income swings to USD 31.38 million; selling, general and administrative expense rises 72% to USD 50.37 million

Soleno Therapeutics Inc

Soleno Therapeutics Inc

SLNO

0.00
  • Soleno Therapeutics swung to net income of USD 31.38 million for quarter ended March 31, 2026, from a net loss of USD 43.77 million a year earlier.
  • Product revenue, net reached USD 94.6 million, compared with no product revenue a year earlier, as VYKAT XR sales continued following FDA approval in March 2025.
  • Operating income was USD 31.28 million, versus an operating loss of USD 45.74 million a year earlier, while selling, general and administrative expense climbed 72% to USD 50.37 million.
  • Cash and cash equivalents totaled USD 133 million at March 31, 2026, alongside USD 396 million of marketable securities.
  • Neurocrine agreed to buy all shares in a cash tender offer priced at USD 53 per share, launched April 20, 2026 and expected to close in quarter ending June 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-212205), on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.